
DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ	
<u>L5</u> (flt3\$)same(tumor\$or tumour\$ or cancer\$)	19 <u>L5</u>
DB=PGPB, $USPT$ ; $PLUR=YES$ ; $OP=ADJ$	
<u>L4</u> (flt3\$)same(tumor\$or tumour\$ or cancer\$)	97 <u>L4</u>
<u>L3</u> flt3? same (administ\$ augment\$ or enhanc\$ or increas\$ or stimulat\$)same(immun\$ or adjuvant\$ or vaccin\$)	32 <u>L3</u>
<u>L2</u> L1 and flt3\$	2 <u>L2</u>
<u>L1</u> brasel.in.	13 <u>L1</u>

# END OF SEARCH HISTORY



<u>L4</u> (flt3\$)same(tumor\$or tumour\$ or cancer\$)	97 <u>L4</u>
flt3? same (administ\$ augment\$ or enhanc\$ or increas\$ or stimulat\$)same(immun\$ or adjuvant\$ or vaccin\$)	32 <u>L3</u>
<u>L2</u> L1 and flt3\$	2 <u>L2</u>
<u>L1</u> brasel.in.	13 <u>L1</u>

# END OF SEARCH HISTORY

WEST Refine Search

Page 1 of 1

DB=EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ	
<u>L5</u> (flt3\$)same(tumor\$or tumour\$ or cancer\$)	19 <u>L5</u>
DB=PGPB,USPT; PLUR=YES; OP=ADJ	
<u>L4</u> (flt3\$)same(tumor\$or tumour\$ or cancer\$)	97 <u>L4</u>
$\underline{L3}$ flt3? same (administ\$ augment\$ or enhanc\$ or increas\$ or stimulat\$)same(immun\$ or adjuvant\$ or vaccin\$)	32 <u>L3</u>
<u>L2</u> L1 and flt3\$	2 <u>L2</u>
<u>L1</u> brasel.in.	13 <u>L1</u>

# END OF SEARCH HISTORY

Search Results - Record(s) 1 through 10 of 19 returned.					
1. WO003070899A2. 19 Feb 03. 28 Aug 03. PHOSPHO-SPECIFIC ANTIBODIES TO FLT3 ND USES THEREOF. COMB, MICHAEL J, et al. C12N00/;.					
☐ 2. <u>EP001109020A1</u> . 19 Aug 99. 20 Jun 01. METHOD FOR SCREENING CANDIDATE COMPOUNDS FOR DRUG AGAINST TUMOR. KIYOI, HITOSHI, et al. G01N033/50; G01N033/15					
3. WO009926639A1. 24 Nov 98. 03 Jun 99. METHODS FOR MOBILIZING HEMATOPOIETIC FACILITATING CELLS AND HEMATOPOIETIC STEM CELLS INTO THE PERIPHERAL BLOOD. ILDSTAD, SUZANNE T, et al. A61K035/12; A61K035/28 A61K038/18 A61K038/19 A61K038/20 C12N005/00.					
☐ 4. <u>WO009428391A1</u> . 12 May 94. 08 Dec 94. LIGANDS FOR FLT3 RECEPTORS. LYMAN, STEWART D, et al. 424/85.2. G01N001/34; G01N033/48 C12N005/00 C12N001/21 A61K037/02 A61K048/00 C07K013/00 C07K015/28 C07H021/04 C12N015/12 C12N015/64 A01K067/00.					
☐ 5. <u>EP000627487A2</u> . 19 May 94. 07 Dec 94. Ligands for FLT3 receptors LYMAN, STEWART D, et al. C12N015/00;.					
☐ 6. <u>US20040037845A</u> . Treating a bacterial or a viral infection and increasing the number of dendritic cells in a patient, comprises administering an fms-related tyrosine kinase 3-ligand. BRASEL, K, et al. A61K039/00.					
7. WO2003083083A. Immunization protocols to enhance immune responses against vaccine antigens using an Flt3-ligand, useful for preventing or treating viral or bacterial infections, cancer, allergies, and fungal, parasitic and protozoal infections. LIEBOWITZ, D N, et al. A61K038/19 A61K038/20 A61K038/21 A61K039/00 C12N000/00.					
8. WO2003070899A. New FMS-related tyrosine kinase 3 antibodies phosphorylated at tyrosine 589 or tyrosine 591 useful for diagnosing and monitoring the progression of cancer. COMB, M J, et al. C07K016/40 C12N000/00 C12N005/06 C12P021/04 G01N033/53.					
9. <u>US20030113341A</u> . Treating <u>cancer</u> , increasing the number of dendritic cells, augmenting tumor-specific immune response, and increasing tumor rejection in a patient having <u>cancer</u> by administering a composition comprising <u>Flt3-ligand</u> . BORGES, L, et al. A61K039/00.					
☐ 10. WO2002100317A. Non-cellular particle (e.g. of human immunodeficiency virus), for drug delivery, prophylaxis against viruses and cancer, and treating autoimmune diseases, comprises a nuclei acid and/or a fusion protein having an Flt-3 ligand. MUTHAMANI, K, et al. A61J000/00.					
Generate Collection Print					
Term Documents					
FLT3\$					
FLT3 82					

### **Search Results** - Record(s) 1 through 2 of 2 returned.

### ☐ 1. Document ID: US 20040037845 A1

### Using default format because multiple data bases are involved.

L2: Entry 1 of 2

File: PGPB

Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040037845

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040037845 A1

TITLE: Use of flt3-ligand in the treatment of infection

PUBLICATION-DATE: February 26, 2004

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Brasel, Kenneth	Seattle	WA	US	
Lyman, Stewart D.	Seattle	WA	US	
Maraskovsky, Eugene	Seattle	WA	US	
McKenna, Hilary R.	Seattle	WA	US	
Lynch, David H.	Bainbridge Island	WA	US	

US-CL-CURRENT: <u>424/185.1</u>; <u>514/12</u>

	Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw, De
***************************************													
		2. I	Oocume	nt ID:	US 20	020034517	A1						
I	.2: E	ntry	2 of 2	2			Fi	ile: PGP	В		Mar	21,	2002

PGPUB-DOCUMENT-NUMBER: 20020034517

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020034517 A1

TITLE: DENDRITIC CELL STIMULATORY FACTOR

PUBLICATION-DATE: March 21, 2002

#### INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	<b>RULE-47</b>
BRASEL, KENNETH	SEATTLE	WA	US	
LYMAN, STEWART D.	SEATTLE	WA	US	
MARASKOVSKY, EUGENE	SEATTLE	WA	AU	
MCKENNA, HILARY J	SEATTLE	WA	US	
LYNCH, DAVID H.	BAINBRIDGE ISLAND	WA	US	
MALISZEWSKI, CHARLES R.	SEATTLE		US	

US-CL-CURRENT: 424/192.1; 424/198.1, 435/325, 435/372.3, 530/351

Full Title Citation Front Review Classification Date Reference Sequences Attachments Claims KWIC Draw De Clear Generate Collection Print Fwd Refs Bkwd Refs

Term	Documents
FLT3\$	0
FLT3	809
FLT3B1	4
FLT3C	1
"FLT3C.SEQ"	1
FLT3F1	4
FLT3L	100
FLT3LG	9
FLT3LIG	2
FLT3LIGAND	2
FLT3L-DERIVED	1
(L1 AND FLT3\$).PGPB,USPT.	2

Search	Results -	Record(s	) 11	through	19 o	f 19	returned.

Search Results 100014(b) 11 through 15 of 15 retained.
11. <u>US20020034517A</u> . Augmenting an immune response in a patient using <u>flt3-ligand</u> to increase the number of dendritic cells is useful to treat infectious disease such as HIV infection, and neoplastic diseases such as <u>cancer</u> . BRASEL, K, et al. A61K039/00 A61K045/00 C07K001/00 C07K014/00 C07K017/00 C12N005/00 C12N005/02 C12N005/08.
☐ 12. <u>US 6291660B</u> . New mutant <u>flt3-ligand</u> polypeptide and nucleic acid, useful in allogeneic or autologous transplantation, treating immune disorders, <u>cancer</u> , aplastic anemia and for inducing cellular differentiation. DIETRICH, F, et al. C07H021/04.
☐ 13. <u>KR2001046513A</u> . In vitro amplification method of peripheral blood stem cell using three-dimensional mixed incubation method. JUNG, Y J, et al. C12N005/08.
14. WO 200112208A. Use of Ginkgo biloba extracts or isolated Ginkgolide B for the treatment of cancers caused by the deregulation of expression of proteins involved in regulating tumor cells e.g. breast and colon cancers. DRIEU, K, et al. A61K000/00 A61K031/34 A61K031/365 A61K035/78 A61P035/00 A61P043/00.
☐ 15. WO 200045178A. A kit for assessing the myelosuppressive state of a patient, for optimizing myelosuppressive therapy comprises a cytokine-specific detection reagent. ALISAUSKAS, R, et al. C07K016/24 G01N033/53 G01N033/567 G01N033/68.
☐ 16. <u>US 6291661B</u> . Mutant soluble flt3 ligand polypeptide used in cellular expansion, immune response stimulation or treatment of pathological conditions contains amino acid substitutions at positions 8, 84, 118 or 122. GRADDIS, T J, et al. A61K038/19 C07H021/04 C07K014/475 C07K014/52 C07K019/00 C12N005/06 C12N015/19 C12P021/02.
☐ 17. <u>US 6218371B</u> . Novel synergistic combinations of immunostimulatory oligonucleotides and immunopotentiating cytokines are useful for stimulating the immune system. KRIEG, A M, et al. A01N037/18 A01N043/04 A61K031/70 A61K031/7088 A61K038/00 A61K038/19 A61K039/00 A61K048/00 A61P015/00 A61P035/00 A61P037/04 C07H021/02 C12Q001/68.
□ 18. <u>WO 9712633A</u> . Use of flt3-ligand - for increasing numbers of dendritic cells for augmenting immune responses to infections, tumours or vaccine antigens. BRASEL, K, et al. A01N001/02 A61K031/00 A61K035/12 A61K038/00 A61K038/17 A61K039/00 A61K039/02 A61K039/12 A61K039/21 A61K039/39 A61K045/00 A61K045/05 C07K014/475 C12N005/00 C12N005/06 C12N005/10 C12N015/09.
☐ 19. EP 699236B. New ligand for the Flt3 tyrosine kinase receptor - and related nucleic acid, vectors, host cells and antibodies, useful for treating abnormal cell physiology and proliferation, e.g. cancer, also for diagnosis and drug screening. BIRNBAUM, D, et al. A61K037/02 A61K038/00 A61K038/17 A61K038/18 A61K039/00 A61K039/395 C07H021/04 C07K013/00 C07K014/47 C07K014/475 C07K016/18 C07K016/42 C07K019/00 C12N001/21 C12N005/10 C12N015/02 C12N015/09 C12N015/12 C12N015/85 C12P021/02 C12P021/08 C12Q001/68 G01N033/68 C12P021/02 C12R001:91.
Generate Collection Print